Practice Management
The respiratory syncytial virus (RSV) vaccine manufactured by Moderna, Inc. received approval last week by the Food and Drug Administration to prevent lower respiratory tract disease caused by RSV in individuals 18-59 years of age who are at increased risk for disease. The vaccine was previously approved in May 2024 for adults aged 60 years and older, according to a press release, and this new approval expands the age range for use to a younger …
Read More
The real-world effectiveness of the respiratory syncytial virus (RSV) vaccination among U.S. adults aged 60 years and older during the 2023–2024 RSV season was found to be 75.1% (95% confidence interval, 73.6–76.4%), according to research published in JAMA Network Open. Vaccine effectiveness was evaluated against acute respiratory infection, urgent care or emergency department visits, and hospitalizations. Among those 60 years and younger, the vaccine was 75.8% effective (73.2-78.1%) against urgent care or emergency department visits …
Read More
Older adults who receive the respiratory syncytial virus (RSV) vaccine are 75% less likely to be hospitalized from RSV compared to those who are not vaccinated, according to a research letter in JAMA. By analyzing electronic medical record data from October 2023 to March 2024 for adults aged 60 years and older who were hospitalized with an acute respiratory illness, researchers selected a control group of 2,611 patients—who tested negative for RSV, COVID-19, and influenza—and …
Read More
The Centers for Disease Control and Prevention (CDC) recently updated vaccine guidance after its advisory committee recommended that all adults aged 75 years and older and adults aged 60–74 years who are at increased risk should receive a single dose of a respiratory syncytial virus (RSV) vaccine. The update reflects CDC’s intent to maximize RSV vaccination coverage among those most likely to benefit and to reduce implementation barriers associated with a previous recommendation that called …
Read More